Global Primary Sclerosing Cholangitis Market – Industry Trends and Forecast to 2028

Market Analysis and Insights of Primary Sclerosing Cholangitis Market

Rising prevalence of liver diseases coupled with increasing alcohol consumption are attributable to the growth of primary sclerosing cholangitis market. Data Bridge Market Research analyses that the primary sclerosing cholangitis will exhibit a CAGR of around 4.02% for the forecast period of 2021-2028.

Primary sclerosing cholangitis is a rare disease that has an impact on bile duct. The bile duct becomes scarred in primary sclerosing cholangitis. This in turn affects the functioning of liver. In other words, primary sclerosing cholangitis is a chronic disease that affects the liver and the gallbladder. It is mostly observed in men in the age group of 30-50 years. It leads to clogging of bile ducts leading to accumulation of bile acids, which in turn damages the liver tissues.

Rising prevalence of liver diseases globally is fostering the growth of primary sclerosing cholangitis market. Rising cases of bile cancer due to bad lifestyle is also inducing the growth of primary sclerosing cholangitis market. Large number of pipeline molecules is set to further foster the market growth.

However, withdrawal of molecules from late clinical stages will hamper the market growth. Lack of initiatives by the government to spread the awareness and undertake research and development activities in this direction will further restrain the scope of growth. Lack of skilled professionals or trained expertise in this area in low and middle class economies will further create hindrances in the way of growth.

This primary sclerosing cholangitis market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on primary sclerosing cholangitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Primary Sclerosing Cholangitis Market Scope and Market Size

The primary sclerosing cholangitis market is segmented on the basis of type, treatment type, symptom control and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• Based on the type, the primary sclerosing cholangitis market has been segmented into classic PSC, small-duct PSC and PSC associated with autoimmune hepatitis.
• On the basis of treatment type, the primary sclerosing cholangitis market is segmented into ursodeoxycholic acid, obeticholic acid, methotrexate, corticosteroids and others.
• On the basis of symptom control, the primary sclerosing cholangitis market is segmented into antihistamines, cholestyramine, antibacterials, opioid antagonists, colestipol and others.
• On the basis of end user, the primary sclerosing cholangitis market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.

Primary Sclerosing Cholangitis Market Country Level Analysis

The primary sclerosing cholangitis market is analysed and market size insights and trends are provided by country, type, treatment type, symptom control and end user as referenced above.

The countries covered in the primary sclerosing cholangitis market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the primary sclerosing cholangitis market owing to the prevalence of sophisticated healthcare infrastructure, increased research and development proficiencies by the pharmaceutical companies and rapid adoption of new and better healthcare technologies. Favourable reimbursement policies are also inducing the dominance of the region. Asia-Pacific on the other hand is projected to score highest growth rate for the forecast period owing to rising expenditure to develop healthcare infrastructure and rising prevalence of liver diseases and disorders.

The country section of the primary sclerosing cholangitis market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The primary sclerosing cholangitis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for clinical trial imaging market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the primary sclerosing cholangitis market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Primary Sclerosing Cholangitis Market Share Analysis

The primary sclerosing cholangitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to primary sclerosing cholangitis market.

The major players covered in the primary sclerosing cholangitis market report are Glenmark Pharmaceuticals Limited, Zydus Pharmaceuticals, Inc., Merck & Co., Inc., Sanofi, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited., F. Hoffmann-La Roche Ltd, Abbott, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Bristol-Myers Squibb Company, Amneal Pharmaceuticals LLC., HighTide Therapeutics Inc., Sirnaomics, Inc., Allergan, Acorda Therapeutics, Inc., Gilead Sciences, Inc. and NGM Biopharmaceuticals. among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-36313